Inflammatory cytokines in heart failure: Mediators and markers

Cardiology (Switzerland)

Volumn 122, Issue 1, 2012, Pages 23-35

  Gullestad, Lars ^a,c   Ueland, Thor ^b   Vinge, Leif Erik ^a,b   Finsen, Alexandra ^a,b   Yndestad, Arne ^b   Aukrust, Pal ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiac remodeling; Chronic heart failure; Immunomodulating treatment; Inflammatory mediators; Markers

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIOTROPHIN 1; CD27 ANTIGEN; CYTOKINE; ENALAPRIL; ETANERCEPT; FAS LIGAND; FRACTALKINE; GALECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OXIPURINOL; PATTERN RECOGNITION RECEPTOR; PENTOXIFYLLINE; PENTRAXIN 3; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROSUVASTATIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CORONARY ARTERY DISEASE; CYTOKINE RESPONSE; DRUG MEGADOSE; EXTRACELLULAR MATRIX; HEART EJECTION FRACTION; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LEUKOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TH1 CELL; UNSPECIFIED SIDE EFFECT; UPREGULATION;

BIOLOGICAL MARKERS; CHRONIC DISEASE; CYTOKINES; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; MYOCARDITIS;

EID: 84862177457     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000338166     Document Type: Article

References (105)

1. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-382. (Pubitemid 29066497)
2. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel T: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-971. (Pubitemid 26348163)
3. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-1206. (Pubitemid 26117714)
4. Aukrust P, Ueland T, Muller F, Andreassen AK, Aass H, Kjekshus J, Simonsen S, Frøland SS, Gullestad L: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-1143. (Pubitemid 28152886)
5. Damås JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Frøland SS, Aukrust P: CXCchemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 2000; 45: 428-436. (Pubitemid 30069508)
6. Kapadia S: Cytokines and heart failure. Cardiol Rev 1999; 7: 196-206. (Pubitemid 29316247)
7. Deveaux B, Scholz D, Hirche A, Kløverkorn WP, Schaper J: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997; 18: 470-479. (Pubitemid 27110479)
8. Damås JK, Eiken HG, Øie E, Bjerkeli V, Yndestad A, Ueland T, Tønnesen T, Geiran O, Aass H, Simonsen S, Christensen G, Frøland SS, G.Attramadal H, Gullestad L, Aukrust P: Myocardial expression of CC-and CXC-chemokines and their receptors in human endstage heart failure. Cardiovasc Res 2000; 47: 778-787.
9. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure. Circulation 2001; 103: 2055-2059.
10. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive dysfunction and remodelling in rats. Circulation 1998; 97: 1382-1391. (Pubitemid 28182677)
11. Kubota T, McTernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-635. (Pubitemid 27432751)
12. Fischer P, Hilfiker-Kleiner D: Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 2008; 153:(suppl 1):S414-S427. (Pubitemid 351341017)
13. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998. (Pubitemid 35416635)
14. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA: Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 2001; 98: 2871-2876. (Pubitemid 32209576)
15. Lecour S, James RW: When are pro-inflammatory cytokines SAFE in heart failure? Eur Heart J 2011; 32: 680-685.
16. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S: Cytokine gene expression after myocardial infarction in rat hearts. Circulation 1998; 98: 149-156.
17. Borlaug BA, Redfield MM: Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2014; 123: 2006-2013.
18. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ: Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113: 1966-1973.
19. Dinh W, Futh R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, Barroso MC, Lankisch M: Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Diabet Med 2011; 28: 311-318.
20. Zibadi S, Vazquez R, Larson DF, Watson RR: T lymphocyte regulation of lysyl oxidase in diet-induced cardiac fibrosis. Cardiovasc Toxicol 2010; 10: 190-198.
21. Yu Q, Horak K, Larson DF: Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension 2006; 48: 98-104. (Pubitemid 44297530)
22. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL: Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225-231.
23. Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF: IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol 2009; 297:H76-H85.
24. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von SJ, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C: Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circulation Heart Fail 2011; 4: 44-52.
25. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ: Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817.
26. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D: Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010; 106: 1646-1655.
27. Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Øie E, Vinge LE, Sjaastad I, Sandanger Ø, Ranheim T, Dickstein K, Kjekshus J, Damås JK, Fiane A, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P: The homeostatic chemikine CCL21 predicts mortality and may play a pathogenic role in heart failure. PLoS One 2012; 7:e33038.
28. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM: Nterminal pro-B-type natriuretic peptideguided treatment for chronic heart failure: results from the BATTLESCARRED (NTproBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53-60.
29. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN; Val-HeFT Investigators: C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112: 1428-1434. (Pubitemid 41291768)
30. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120: 2188-2196.
31. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I: Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81. (Pubitemid 350234768)
32. Orus J, Roig E, Perez-Villa F, Pare C, Az-queta M, Filella X, Heras M, Sanz G: Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 2000; 19: 419-425. (Pubitemid 30249079)
33. Dempsey PW, Doyle SE, He JQ, Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 193-209. (Pubitemid 36693141)
34. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1479-1486.
35. Roysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Misuraca G, Maggioni AP, Tognoni G, Tavazzi L, Latini R; GISSI-HF Investigators: Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010; 160: 286-293.
36. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Bohm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L: Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011; 4: 145-152.
37. Gwechenberger M, Pacher R, Berger R, Zorn G, Moser P, Stanek B, Huelsmann M: Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. J Heart Lung Transplant 2005; 24: 2190-2195. (Pubitemid 41814745)
38. Henderson NC, Sethi T: The regulation of inflammation by galectin-3. Immunol Rev 2009; 230: 160-171.
39. Ueland T, Aukrust P, Broch K, Aakhus S, Skårdal R, Muntendam P, Gullestad L: Galectin-in heart failure: high levels are associated with all cause mortality. Int J Cardiol 2011; 150: 361-364.
40. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM: Utility of amino-terminal probrain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-1224. (Pubitemid 44345127)
41. Lok DJA, Van Der Mer P, de la Porta PW-A, Lipsic E, Hillege HL, van Veldhuisen DJ: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-328.
42. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Fowler MB: Effect of highversus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061-2067. (Pubitemid 30002665)
43. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Frøland SS, Aukrust P: Effect of metoprolol on cytokine levels in chronic heart failure-a substudy in the Metoprolol Controlled-Release Randomized Intervention Trial in Heart Failure (MERIT-HF trial). Am Heart J 2001; 141: 418-421. (Pubitemid 32200270)
44. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K: Effects of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 412-417.
45. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch CB, Mann DL: Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-3226. (Pubitemid 29293430)
46. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, van Veldhuisen DJ, Waldenstrøm A, Warren M, Westheim A, Zannad F, Fleming T: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-1602. (Pubitemid 38451714)
47. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators: Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-tosevere heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3040.
48. Lugering A, Schmidt M, Lugering N, Pauels HG, Domscke W: Infliximab induces apoptosis in myocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157. (Pubitemid 33022095)
49. Gullestad L, Aass H, Fjeld JG, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland SS, Aukrust P: Effect of immunomodulating therapy with intravenous immunoglobulin in chronic congestive heart failure. Circulation 2001; 103: 220-225. (Pubitemid 32095406)
50. Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R: Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 285-391.
51. Larsson L, Mobini R, Aukrust P, Gullestad L, Wallukat G, Waagstein F, Fu M: Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with cardiomyopathy is not due to neutralization of anti-adrenoceptor antibody. Autoimmunity 2004; 37: 489-493. (Pubitemid 40123419)
52. Gullestad L, Ueland T, Fjeld J, Holt E, Gundersen T, Breivik K, Følling M, Hodt A, Skårdal R, Kjekshus J, Andreassen AK, Kjekshus E, Wergeland R, Yndestad A, Frøland SS, Semb AG, Aukrust P: The effect of thalidomide on cardiac remodeling in chronic heart failure: results of a doubleblind placebo-controlled study. Circulation 2005; 112: 3408-3414. (Pubitemid 43739555)
53. Nolan Y, Minogue A, Vereker E, Bolton AE, Campbell VA, Lynch MA: Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's Immune Modulation Therapy. Neuroimmunomodulation 2002; 10: 40-46. (Pubitemid 35007464)
54. Torre-Amione G, Sestier F, Radovancevic B, Young J: Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004; 44: 1181-1186. (Pubitemid 39208871)
55. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moye LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR, Young JB; Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators: Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008; 371: 228-236.
56. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 344: 1383-1389.
57. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
58. Kwak B, Mulhaup F, Mylt S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402. (Pubitemid 32001026)
59. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261. (Pubitemid 350190755)
60. GISSI-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet 2008; 372: 1231-1239.
61. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN: Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-1356. (Pubitemid 28219127)
62. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP; OPT-CHF Investigators: Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51: 2301-2309. (Pubitemid 351783365)
63. Takeuchi O, Akira S: Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
64. Nathan C, Ding A: Nonresolving inflammation. Cell 2010; 140: 871-882.
65. Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human tolllike receptors and related genes. Biol Pharm Bull 2005; 28: 886-892. (Pubitemid 40740661)
66. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104: 271-280.
67. Frantz S, Kelly RA, Bourcier T: Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 2001; 276: 5197-5203.
68. Nemoto S, Vallejo JG, Knuefermann P, Misra A, DeFreitas G, Carabello BA, Mann DL: Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol 2002; 282:H2316-H2323. (Pubitemid 34663043)
69. Mann DL: The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108: 1133-1145.
70. Frantz S, Ertl G, Bauersachs J: Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444-454. (Pubitemid 47180328)
71. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, Verrier ED: Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006; 114(1 suppl):I270-I274. (Pubitemid 44297162)
72. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP: Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010; 121: 80-90.
73. Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Ann Rev Immunol 2009; 27: 229-265.
74. Bergamini C, Cicoira M, Rossi A, Vassanelli C: Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009; 11: 444-452.
75. Vassort G: Adenosine 5-triphosphate: a P2-purinergic agonist in the myocardium. Physiol Rev 2001; 81: 767-806. (Pubitemid 32273137)
76. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U: Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011; 123: 594-604.
77. Sasayama S, Okada M, Matsumori A: Chemokines and cardiovascular diseases. Cardiovasc Res 2000; 45: 267-269. (Pubitemid 30069490)
78. Kolattukudy PE, Quasch T, Berges S: Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 1998; 152: 101-111. (Pubitemid 28028051)
79. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, Wen J, Egashira K, Takeshita A: Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003; 108: 2134-2140. (Pubitemid 37337591)
80. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O: Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995; 269: 1583-1585.
81. Tachibana K, Hirota S, Ilzasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Nagasawa T: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393: 524-525.
82. Husberg C, Nygard S, Finsen AV, Damas JK, Frigessi A, Oie E, Waehre A, Gullestad L, Aukrust P, Yndestad A, Christensen G: Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45: 261-269.
83. Xuan W, Liao Y, Chen B, Xu D, Liu Y, Kitakaze M: Detrimental effect of fractaline on myocardial ischemia and heart failure. Cardiovasc Res 2011; 92: 361-362.
84. Dahl CP, Husberg C, Gullestad L, Waehre A, Damas JK, Vinge LE, Finsen AV, Ueland T, Florholmen G, Aakhus S, Halvorsen B, Aukrust P, Oie E, Yndestad A, Christensen G: Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Circ Heart Fail 2009; 2: 624-632.
85. Waehre A, Halvorsen B, Yndestad A, Husberg C, Sjaastad I, Nygard S, Dahl CP, Ahmed MS, Finsen AV, Reims H, Louch WE, Hilfiker-Kleiner D, Vinge LE, Roald B, Attramadal H, Lipp M, Gullestad L, Aukrust P, Christensen G: Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload. PLoS One 2011; 6:e18668.
86. Walsh MC, Choi Y: Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003; 14: 251-263. (Pubitemid 36693145)
87. Feng W, Li W, Liu W, Wang F, Li Y, Yan W: IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 2009; 87: 212-218.
88. Ueland T, Yndestad A, Øie E, Florholmen G, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P: Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461-2468. (Pubitemid 40696134)
89. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson A-KL, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P: Enhanced T cell expression of RANK ligand in acute coronary syndrome-possible role in plaque progression. Arterioscler Thromb Vasc Biol 2006; 26: 857-863. (Pubitemid 43732163)
90. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16: 348-360. (Pubitemid 32105416)
91. Rachner TD, Khosla S, Hofbauer LC: Osteoporosis: now and the future. Lancet 2011; 377: 1276-1287.
92. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
93. Murray DB, Levick SP, Brower GL, Janicki JS: Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha. J Mol Cell Cardiol 2010; 49: 245-250.
94. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y: Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005; 115: 599-609. (Pubitemid 40322234)
95. Vanhoutte D, Heymans S: TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010; 48: 445-453.
96. Cheung C, Marchant D, Walker EK, Luo Z, Zhang J, Yanagawa B, Rahmani M, Cox J, Overall C, Senior RM, Luo H, McManus BM: Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008; 117: 1574-1582. (Pubitemid 351440645)
97. Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li RK, Khokha R: TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 2004; 110: 2401-2409. (Pubitemid 39407346)
98. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000; 97: 12746-12751.
99. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R: Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005; 97: 380-390. (Pubitemid 41216143)
100. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGFbeta activation. J Cell Sci 2003; 116: 2-24.
101. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-111. (Pubitemid 23188802)
102. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, Takeshita A: Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004; 64: 526-535. (Pubitemid 39505431)
103. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, Zambakides C, Peters F, Essop R: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004; 109: 750-755. (Pubitemid 38222895)
104. Staudt A, Schaper F, Stangl V, Plagemann A, Bøhm M, Merkel K, Wallukat G, Wernecke KD, Stangl K, Baumann G, Felix SB: Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001; 103: 2681-2686. (Pubitemid 32538782)
105. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-2259. (Pubitemid 32433714)